Unmet needs in nasopharyngeal cancer therapeutics continue to frustrate clinicians

Clinicians treating patients with nasopharyngeal cancer may have to wait for the scientific breakthrough they seek, as university-funded research on unique treatments may fail to offer a fast alternative, a new report by pharmaceutical market experts GlobalData has found.

The new report shows that while the significant risks associated with current treatment options have led medical professionals to demand a new blockbuster drug, research currently being undertaken at various academic institutions around the world lacks the financial backing needed to make a considerable impact on the treatment market.

Current products for nasopharyngeal cancer put patients at risk of several adverse side effects, including neutropenia, thrombocytopenia, anemia, leucopenia and infections resulting from the loss of white blood cells. The global nasopharyngeal cancer therapeutics market therefore offers considerable opportunity for new products to capture market value if they can offer superior efficacy and safety profiles, alongside fewer adverse effects.